KDR and neuroblastoma: VEGF-R2 sequence-specific siRNA encapsulated with RGD-PEG-PEI (RPP) was subjected to an in vivo study for assessing the antitumor activity against a neuroblastoma tumor developed by administrating 1 × 106 of N2A cells (mouse neuroblastoma cells) into the flank of the female nude mice (6–8 weeks old).